



Training session : Essential 6[®] spot-on latest publications





**Mane-tain your
best self!**

Dandruff
Excessive hair loss
Hyperkeratosis
Greasy skin and coat
Bad odors
Ichthyosis
Sebaceous adenitis

?

Essential line

To help manage
kerato-seborrheic disorders



REGULATING

To help manage kerato-seborrheic disorders

Essential 6[®] spot-on

Hydrating and regulating spot-on
for dogs, cats and small mammals



Dermoscent BIO BALM[®]

Repairing and protective balm

Made in France by Nextmune



Essential Mousse[®]

Rinse-free cleansing foam
for dogs, cats and small mammals

Essential 6[®] Sebo Shampoo

Sebo-regulating shampoo

Essential 6[®] spot-on

Hydrating & regulating spot-on



INDICATION

Skin disorders: dandruff, bad odors, hair loss, dull/brittle hair, greasy or dry skin

Sebaceous adenitis & ichthyosis

To maintain skin balance and repair the barrier function

Helps:

- Hydrate, and reinforce the cutaneous barrier
- Regulate skin and coat dryness or greasiness
- Diminish hair loss (excluding seasonal molt)
- Diminish dandruff
- Deodorize
- Protect with its antioxidant effect



Helps space out shampoo
Substitute daily intake of oral omega 3 & 6

Initial care: 1 pipette/ week during 2 consecutive months

Maintenance: 1 pipette every 2 weeks as long as necessary



4 pipettes

100% NATURAL ACTIVE INGREDIENTS

- Hemp seed oils rich in EFA
- Synergy of essential oils: rosemary, lavender, clove, cedar, oregano, peppermint, camphor, turmeric, wintergreen, tea tree
- Vitamin E

SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs : a comparative controlled study.

E.Bensignor, M. Larher, M.Cauquil, J.Pattyn

A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs: a comparative controlled study



E. BENSIGNOR^{1,2}, M. LARHER³, M. CAUQUIL⁴, J. PATTYN⁵

¹Dermatology Service, Department of clinical sciences, Orléans Nantes Veterinary School, France
²Dermatology Dermatology Internal Service, Paris Lodron Veterinary School, France
³Veterinary Clinic, Rennes Croisson, France
⁴LDC/Nextmune, Caennas, France

INTRODUCTION

Treatment of granulomatous sebaceous adenitis (GSA) is not codified. Therapy revolves around removing scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present. Ciclosporin has been demonstrated to be useful either alone or even better in association with topical treatments such as shampoos and sprays (1).

OBJECTIVE

The aim of this comparative controlled study was to determine if the combination of a topical treatment with a spot-on containing rehydrating and antiseborrheic agents (**Dermoscent Essential[®] 6 spot-on**, Nextmune formerly LDCA) could allow to reduce the doses of ciclosporin on a long term in dogs suffering from GSA.

MATERIALS & METHODS

This was a retrospective case-control comparative study including dogs diagnosed with GSA, based on compatible clinical signs (scaling/follicular casts) and histopathological lesions (histiocytic inflammation centered on sebaceous glands or absence of sebaceous glands). Two groups were retrospectively compared:

- Group A : 5 dogs treated with ciclosporin alone (5 mg/kg/day, Cycloavance[®], Virbac)
- Group B : 6 dogs treated with ciclosporin (5 mg/kg/day, Cycloavance[®]) in association with weekly applications of the tested product (**Essential[®] 6 spot-on**).

A first follow-up visit was performed after one month and ciclosporin dosage was then progressively reduced as clinical signs improved. In each group, average doses were retrospectively calculated after the three- and six-month follow-up visits (D90 and D180 respectively).

RESULTS

- At D90, no statistically significant difference was observed in ciclosporin dosage between groups A and B (4.7 and 5.08 mg/kg/day respectively).
- At D180, dogs in group B received a significantly lesser dosage of ciclosporin (4.44 for group A and 2.98 mg/kg/day for group B, P<0.05, repeated measures two-way ANOVA).
- Compared to the initial dose at D0 (5 mg/kg/day), ciclosporin dosage was reduced in 4/5 dogs in group A and 5/6 in group B at D180 (group A vs B: not statistically significant, Fischer's exact test).
- However, ciclosporin dosage was significantly reduced by more than 20% in 5/6 in group B and in 1/5 in group A at D180 (group A vs B: P<0.05, Fischer's exact test).




Figure 1: Ciclosporin dosage. Data are expressed as means ± SD. * P<0.05



Figure 2: Evolution of ciclosporin dosage in each dog.

CONCLUSION

These results suggest that the application of Essential 6[®] spot-on for 6 months can have a sparing effect on the use of ciclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

Reference
(1) Lenz, et al. "A multicentre placebo controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment." *Veterinary dermatology* vol. 21,6 (2010): 593-601. doi:10.1111/j.1365-3164.2010.00902.x

Source of funding: self funded.

Conflict of interests: E. Bensignor is consultant for LDCA/Nextmune France and M. Cauquil is an employee of LDCA/Nextmune.

Focus on sebaceous adenitis skin disease :

Sebaceous adenitis is an inflammatory skin disease in which the sebaceous glands are damaged or destroyed, leading to dry skin, scaling, hair loss, and changes in coat quality.



2

SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs : a comparative controlled study.

E.Bensignor, M. Larher, M.Cauquil, J.Pattyn

A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs: a comparative controlled study



E. BENSIGNOR^{1,2}, M. LARHER³, M. CAUQUIL⁴, J. PATTYN⁵



¹Dermatology Service, Department of clinical sciences, Orlins Nantes Veterinary School, France
²Dermatology Dermatology Internal Service, Paris Lodron Veterinary School, France
³Veterinary Clinic, Rennes Cedex 3, France
⁴LDC/Nextmune, Castres, France

INTRODUCTION

Treatment of granulomatous sebaceous adenitis (GSA) is not codified. Therapy revolves around removing scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present. Ciclosporin has been demonstrated to be useful either alone or even better in association with topical treatments such as shampoos and sprays (1).

OBJECTIVE

The aim of this comparative controlled study was to determine if the combination of a topical treatment with a spot-on containing rehydrating and antiseborrheic agents (**Dermoscent Essential[®] 6 spot-on**, Nextmune formerly LDCA) could allow to reduce the doses of ciclosporin on a long term in dogs suffering from GSA.

MATERIALS & METHODS

This was a retrospective case-control comparative study including dogs diagnosed with GSA, based on compatible clinical signs (scaling/follicular casts) and histopathological lesions (histiocytic inflammation centered on sebaceous glands or absence of sebaceous glands). Two groups were retrospectively compared:

- Group A : 5 dogs treated with ciclosporin alone (5 mg/kg/day, Cycloavance[®], Virbac)
- Group B : 6 dogs treated with ciclosporin (5 mg/kg/day, Cycloavance[®]) in association with weekly applications of the tested product (**Essential[®] 6 spot-on**).

A first follow-up visit was performed after one month and ciclosporin dosage was then progressively reduced as clinical signs improved. In each group, average doses were retrospectively calculated after the three- and six-month follow-up visits (D90 and D180 respectively).

RESULTS

- At D90, no statistically significant difference was observed in ciclosporin dosage between groups A and B (4.7 and 5.06 mg/kg/day respectively).
- At D180, dogs in group B received a significantly lesser dosage of ciclosporin (4.44 for group A and 2.98 mg/kg/day for group B, P<0.05, repeated measures two-way ANOVA).
- Compared to the initial dose at D0 (5 mg/kg/day), ciclosporin dosage was reduced in 4/5 dogs in group A and 5/6 in group B at D180 (group A vs B: not statistically significant, Fischer's exact test).
- However, ciclosporin dosage was significantly reduced by more than 20% in 5/6 in group B and in 1/5 in group A at D180 (group A vs B: P<0.05, Fischer's exact test).




Figure 1: Ciclosporin dosage. Data are expressed as means ± SD. * P<0.05




Figure 2: Evolution of ciclosporin dosage in each dog.

CONCLUSION

These results suggest that the application of Essential 6[®] spot-on for 6 months can have a sparing effect on the use of ciclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

Reference

(1) Lenz, et al. "A multicentre placebo controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment." *Veterinary dermatology* vol. 21,6 (2010): 553-601. doi:10.1111/j.1365-3164.2010.00902.x

Source of funding: self funded.

Conflict of interests: E. Bensignor is consultant for LDCA/Nextmune France and M. Cauquil is an employee of LDCA/Nextmune.

1. Introduction

- Treatment of granulomatous sebaceous adenitis (GSA) is **not codified**. Therapy revolves around scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present.
- **Ciclosporin has been demonstrated to be useful** either alone or even better in association with topicals.

SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs : a comparative controlled study.

E.Bensignor, M. Larher, M.Cauquil, J.Pattyn

A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs: a comparative controlled study



E. BENSIGNOR^{1,2}, M. LARHER³, M. CAUQUIL⁴, J. PATTYN⁵



¹Dermatology Service, Department of clinical sciences, Orlins Nantes Veterinary School, France
²Dermatology Dermatology Internal Service, Paris Lodron Veterinary School, France
³Veterinary Clinic, Rennes Croisson, France
⁴LDCA/Nextmune, Caennas, France

INTRODUCTION

Treatment of granulomatous sebaceous adenitis (GSA) is not codified. Therapy revolves around removing scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present. Ciclosporin has been demonstrated to be useful either alone or even better in association with topical treatments such as shampoos and sprays (1).

OBJECTIVE

The aim of this comparative controlled study was to determine if the combination of a topical treatment with a spot-on containing rehydrating and antiseborrheic agents (Dermoscent Essential[®] 6 spot-on, Nextmune formerly LDCA) could allow to reduce the doses of ciclosporin on a long term in dogs suffering from GSA.

MATERIALS & METHODS

This was a retrospective case-control comparative study including dogs diagnosed with GSA, based on compatible clinical signs (scaling/follicular casts) and histopathological lesions (histiocytic inflammation centered on sebaceous glands or absence of sebaceous glands). Two groups were retrospectively compared:

- Group A : 5 dogs treated with ciclosporin alone (5 mg/kg/day, Cyclavance[®], Virbac)
- Group B : 6 dogs treated with ciclosporin (5 mg/kg/day, Cyclavance[®]) in association with weekly applications of the tested product (Essential[®] 6 spot-on).

A first follow-up visit was performed after one month and ciclosporin dosage was then progressively reduced as clinical signs improved. In each group, average doses were retrospectively calculated after the three- and six-month follow-up visits (D90 and D180 respectively).

RESULTS

- At D90, no statistically significant difference was observed in ciclosporin dosage between groups A and B (4.7 and 5.08 mg/kg/day respectively).
- Compared to the initial dose at D0 (5 mg/kg/day), ciclosporin dosage was reduced in 4/5 dogs in group A and 5/6 in group B at D180 (group A vs B: not statistically significant, Fischer's exact test).
- At D180, dogs in group B received a significantly lesser dosage of ciclosporin (4.44 for group A and 2.98 mg/kg/day for group B, P<0.05, repeated measures two-way ANOVA).
- However, ciclosporin dosage was significantly reduced by more than 20% in 5/6 in group B and in 1/5 in group A at D180 (group A vs B: P<0.05, Fischer's exact test).




Figure 1: Ciclosporin dosage. Data are expressed as means ± SD. * P<0.05




Figure 2: Evolution of ciclosporin dosage in each dog.

CONCLUSION

These results suggest that the application of Essential 6[®] spot-on for 6 months can have a sparing effect on the use of ciclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

Reference
(1) Lenz, et al. "A multicentre placebo controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment." *Veterinary dermatology* vol. 21,6 (2010): 593-601. doi:10.1111/j.1365-3164.2010.00902.x

Source of funding: self funded.

Conflict of interests: E. Bensignor is consultant for LDCA/Nextmune France and M. Cauquil is an employee of LDCA/Nextmune.

2. Objective

- Determine if the combination of Essential 6[®] spot-on with treatment (ciclosporin) could allow to **reduce the doses of ciclosporin** on a long -term management in dogs suffering from GSA.



SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs : a comparative controlled study.
E.Bensignor, M. Larher, M.Cauquil, J.Pattyn

A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs: a comparative controlled study



INTRODUCTION
Treatment of granulomatous sebaceous adenitis (GSA) is not codified. Therapy revolves around removing scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present. Ciclosporin has been demonstrated to be useful either alone or even better in association with topical treatments such as shampoos and sprays (1).

OBJECTIVE
The aim of this comparative controlled study was to determine if the combination of a topical treatment with a spot-on containing rehydrating and antiseborrheic agents (**Dermoscent Essential[®] 6 spot-on**, Nextmune formerly LDCA) could allow to reduce the doses of ciclosporin on a long term in dogs suffering from GSA.

MATERIALS & METHODS
This was a retrospective case-control comparative study including dogs diagnosed with GSA, based on compatible clinical signs (scaling/follicular casts) and histopathological lesions (histiocytic inflammation centered on sebaceous glands or absence of sebaceous glands). Two groups were retrospectively compared:
- Group A : 5 dogs treated with ciclosporin alone (5 mg/kg/day, Cycloavance[®], Virbac)
- Group B : 6 dogs treated with ciclosporin (5 mg/kg/day, Cycloavance[®]) in association with weekly applications of the tested product (**Essential[®] 6 spot-on**).

A first follow-up visit was performed after one month and ciclosporin dosage was then progressively reduced as clinical signs improved. In each group, average doses were retrospectively calculated after the three- and six-month follow-up visits (D90 and D180 respectively).

RESULTS
• At D90, no statistically significant difference was observed in ciclosporin dosage between groups A and B (4.7 and 5.06 mg/kg/day respectively).
• Compared to the initial dose at D0 (5 mg/kg/day), ciclosporin dosage was reduced in 4/5 dogs in group A and 5/6 in group B at D180 (group A vs B: not statistically significant, Fischer's exact test).
• At D180, dogs in group B received a significantly lesser dosage of ciclosporin (4.44 for group A and 2.98 mg/kg/day for group B, P<0.05, repeated measures two-way ANOVA).
• However, ciclosporin dosage was significantly reduced by more than 20% in 5/6 in group B and in 1/5 in group A at D180 (group A vs B: P<0.05, Fischer's exact test).




Figure 1: Ciclosporin dosage. Data are expressed as means + SD. * P<0.05




Figure 2: Evolution of ciclosporin dosage in each dog.

CONCLUSION
These results suggest that the application of Essential 6[®] spot-on for 6 months can have a sparing effect on the use of ciclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

Reference
(1) Lenz, et al. "A multicentre placebo controlled clinical trial on the efficacy of oral ciclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment." *Veterinary dermatology* vol. 21,6 (2010): 593-601. doi:10.1111/j.1365-3164.2010.00902.x

Source of funding: self funded.
Conflict of interests: E. Bensignor is consultant for LDCA/Nextmune France and M. Cauquil is an employee of LDCA/Nextmune.

3. Material & method



11 dogs presenting GSA

Group A : 5 dogs treated with ciclosporin alone



Group B : 6 dogs treated with ciclosporin + Essential 6[®] spot-on (weekly application)



Ciclosporin average doses were retrospectively calculated after the 3-and-6 months follow-up visits (D90 and D180)

SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs : a comparative controlled study.

E.Bensignor, M. Larher, M.Cauquil, J.Pattyn

A spot-on product with antiseborrheic properties as a useful adjunctive treatment for granulomatous sebaceous adenitis in dogs: a comparative controlled study



E. BENSIGNOR^{1,2}, M. LARHER³, M. CAUQUIL⁴, J. PATTYN⁵

¹Dermatology Service, Department of clinical sciences, Orléans Nantes Veterinary School, France
²Dermatology Dermatology Internal Service, Paris Lodron Veterinary School, France
³Veterinary Clinic, Rennes Croisson, France
⁴LDC/Nextmune, Caennas, France

INTRODUCTION

Treatment of granulomatous sebaceous adenitis (GSA) is not codified. Therapy revolves around removing scales/follicular casts, rehydrating the skin and decreasing sebaceous gland inflammation when present. Cyclosporin has been demonstrated to be useful either alone or even better in association with topical treatments such as shampoos and sprays (1).

OBJECTIVE

The aim of this comparative controlled study was to determine if the combination of a topical treatment with a spot-on containing rehydrating and antiseborrheic agents (**Dermoscent Essential[®] 6 spot-on**, Nextmune formerly LDC) could allow to reduce the doses of cyclosporin on a long term in dogs suffering from GSA.

MATERIALS & METHODS

This was a retrospective case-control comparative study including dogs diagnosed with GSA, based on compatible clinical signs (scaling/follicular casts) and histopathological lesions (histiocytic inflammation centered on sebaceous glands or absence of sebaceous glands). Two groups were retrospectively compared:

- Group A : 5 dogs treated with cyclosporin alone (5 mg/kg/day, Cycloavance[®], Virbac)
- Group B : 6 dogs treated with cyclosporin (5 mg/kg/day, Cycloavance[®]) in association with weekly applications of the tested product (**Essential[®] 6 spot-on**).

A first follow-up visit was performed after one month and cyclosporin dosage was then progressively reduced as clinical signs improved. In each group, average doses were retrospectively calculated after the three- and six-month follow-up visits (D90 and D180 respectively).

RESULTS

- At D90, no statistically significant difference was observed in cyclosporin dosage between groups A and B (4.7 and 5.08 mg/kg/day respectively).
- At D180, dogs in group B received a significantly lesser dosage of cyclosporin (4.44 for group A and 2.98 mg/kg/day for group B, P<0.05, repeated measures two-way ANOVA).
- Compared to the initial dose at D0 (5 mg/kg/day), cyclosporin dosage was reduced in 4/5 dogs in group A and 5/6 in group B at D180 (group A vs B: not statistically significant, Fischer's exact test).
- However, cyclosporin dosage was significantly reduced by more than 20% in 5/6 in group B and in 1/5 in group A at D180 (group A vs B: P<0.05, Fischer's exact test).




Figure 1: Cyclosporin dosage. Data are expressed as means ± SD. * P<0.05




Figure 2: Evolution of cyclosporin dosage in each dog.


CONCLUSION

These results suggest that the application of **Essential 6[®] spot-on** for 6 months can have a sparing effect on the use of cyclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

Reference
(1) Lenz, et al. "A multicentre placebo controlled clinical trial on the efficacy of oral cyclosporin A in the treatment of canine idiopathic sebaceous adenitis in comparison with conventional topical treatment." *Veterinary dermatology* vol. 21,6 (2010): 553-601. doi:10.1111/j.1365-3164.2010.00902.x

Source of funding: self funded.
Conflict of interests: E. Bensignor is consultant for LDC/Nextmune France and M. Cauquil is an employee of LDC/Nextmune.

4. Results



At 6 months, dogs from group B received a significantly lower dose of cyclosporine:

- Group A: 4,44 mg/kg/j, -11% vs J0
- Group B: 2,98 mg/kg/j, **-40%*** vs D0** and **-33%* vs group A**

*p<0,05, ***p<0,001

5. Conclusion

The application of **Essential 6[®] spot-on** for 6 months can have a sparing effect on the use of cyclosporin in dogs diagnosed with GSA. This spot-on may be a useful adjunctive therapy in cases of GSA.

SCIENTIFIC EVIDENCES

Poster at the WCVD 2024 – efficacy of an oral zinc supplement along with an essential oil spot-on in Pomeranian dogs with hair cycle arrets (alopecia X) : an open label pilot study. Yaong-Hun Kang, Stefan Hobi, Cheol-Yong Hwang.

Efficacy of an oral zinc supplement along with an essential oil spot-on in Pomeranian dogs with hair cycle arrest (alopecia X): an open label pilot study
Yaong-Hun Kang*, Stefan Hobi†, Cheol-Yong Hwang*

*Laboratory of Veterinary Dermatology and the Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea
†Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University, Kowloon, Hong Kong, China

Introduction
Hair cycle arrest (alopecia X) is a non-inflammatory symmetrical hair loss disorder, affecting Nordic breeds such as Pomeranians. Although there is evidence that alopecia X is associated with hormonal, environmental factors, and mitochondrial DNA mutations, the exact pathogenesis is not known yet. Current treatment is limited and includes the use of various hormonal products, microneedling and laser therapy. However, there is no golden standard for managing this disorder because of lack of knowledge, treatment limitations, ethical considerations, or side effects.
In human medicine, numerous supplements are used to treat hair loss. Microcircuits play a key role in the normal function of the hair follicles. Furthermore, there is evidence that different types of alopecia are characterized by lower levels of trace elements compared to their controls.^{1,2} The association between alopecia areata in humans and zinc intake is hypothesized to be due to its role in copper and/or zinc superoxide dismutase, with decreased levels resulting in tissue oxidative damage.³
Keravital is a palatable food supplement, containing numerous vitamins and minerals including zinc. Essential 6® is a dermo-care spot-on, mainly composed of hemp seed oil rich in essential fatty acids (Omega 3 and 6) and essential oils.

Materials & Methods
A total of nine client-owned Pomeranian dogs were recruited after given owner consent.
Inclusion criteria
• Pomeranian dogs with chronic hair loss and a diagnosis of alopecia X
• Dogs less than five years of age
• Exclusion of bacterial folliculitis, demodicosis and hormonal diseases
Exclusion criteria
• Oral steroid therapy, at time of presentation or within the past two months
• Diagnosis of a hormonal disease such as hypothyroidism, hypercortisolism or sex hormone disease
• Melatonin, trilostane, deslorelin, growth hormone, melitane (o, p-DDD), medroxyprogesterone acetate or microneedling treatment for alopecia within the past three months
• Neutering performed within the past three months
Methods
Keravital was given orally once a day, and Essential 6® spot-on was applied once a week onto the skin at the shoulder area over 12 months. The diet was not changed during this period.
A Hair Growth Assessment Scale (HGAS) [0-4] was used to evaluate hair regrowth on the dorsum, ventrum, flanks, limbs, digits, and ventral neck: [0 = No improvement, 1 = 1-25% improvement, 2 = 25-50% improvement, 3 = 50-75% improvement, 4 = 75-100% improvement].
An owner questionnaire was conducted to assess satisfaction of the product efficacy, convenience of drug application, hair quality and hair density. [0 = Strongly disagree, 1 = Disagree, 2 = Agree, 3 = Strongly Agree].
For five dogs, the skin barrier function was assessed via measurement of the transepidermal water loss (TEWL) and skin hydration.
Statistical analysis was performed using One-way ANOVA test, and p-values <0.05 were considered statistically significant.

Results
The response to treatment varied among individuals. HGAS scores improved along the trial (M median: 2 [range: 0-14] and GM median: 5 [range: 0-18]), and owners reported satisfaction with the products' efficacy (M median: 4 [1-5], GM median: 3 [1-5]) and ease of use (ME: 2 [1-5], GM: 3 [2-3]). TEWL significantly decreased over time (mean [SD]: GM 14.0 [8.2] g/h² and GM 15.6 [8.3] g/h²; p=0.003), while the skin hydration increased accordingly (mean [SD]: GM 10.9 [5.3] a.u. and GM 15.6 [9.7] a.u.; p=0.02). The medications used in this study were well tolerated and none of the dogs showed any adverse reactions (figures 1 and 2).

Conclusion
The synergistic use of an oral supplement enriched in zinc together with an essential oil based spot-on, appears to have beneficial effects in enhancing hair regrowth and improving skin hydration in a subset of Pomeranian dogs with alopecia X.

Conflicts of Interest
The products used in the present study were provided by Dermoscent, Castres, France.

References
1. Kang YH, Kim MS, Kang SY, Hwang CY. Clinical characteristics and hair regrowth in hair cycle arrest (alopecia X) in six dogs. Veterinary Dermatology. 2023; Dec 6.
2. Adams M, Bedard J, Hobi S, Hobi C. Clinical efficacy of topical oral zinc supplement in dogs. International Journal of Dermatology. 2021; Oct 15:116-20.
3. Choi S, Yoon H, Kim S, Hwang C, Hwang Y. Evaluation of the efficacy and effectiveness of different supplements for treating hair loss: a systematic review. JAMA Dermatology. 2023; Jan 1;159(1):74-84.
4. Adams M, Hobi S, Hobi C, Hwang C. Evaluation of the efficacy and effectiveness of different supplements for treating hair loss: a systematic review. JAMA Dermatology. 2023; Jan 1;159(1):74-84.

Focus on Alopecia X

Alopecia X is a non-inflammatory hair loss disorder, mainly affecting certain dog breeds, characterized by progressive hair loss without itching or skin infection.



SCIENTIFIC EVIDENCES

Studies available

Study name	Objective	Protocol	Conclusion
<p>Preliminary multicentric open study for dermo-cosmetic evaluation of a spot-on formulation composed of poly-unsaturated fatty acids and essential oils on domestic carnivores.</p> <p>E.BENSIGNOR <i>et al</i> <i>Pratique médicale et chirurgicale de l'animal de compagnie, 2010.</i></p>	<p>Evaluate the beneficial properties of Essential 6[®] spot-on for improving skin status of dogs & cats with kerato-seborrheic disorders.</p>	<ul style="list-style-type: none"> • 210 dogs and 79 cats. • Application of Essential 6[®] spot-on once weekly for 1 month. • Evaluated criteria : coat shine, hair-loss, dandruff, odors, skin balance. 	<p>Essential 6[®] spot-on is effective on pet suffering from KSD. All criteria were improved.</p>
<p>Novel association of Psychrobacter and Pseudomonas with malodor in bloodhound dogs, and the effects of a topical product composed of essential oils and plant derived essential fatty acids in a randomized, blinded, placebo-controlled study.</p> <p>C. MEASON-SMITH <i>et al</i> <i>Veterinary dermatology, 2018.</i></p>	<p>Evaluate the effect of Essential 6[®] spot-on to improve skin barrier and cutaneous imbalances (including malodor dogs) and cause a reduction of bad bacteria.</p>	<p>27 dogs divided into 3 groups :</p> <ol style="list-style-type: none"> 1. Group placebo, dogs with normal body odor 2. Malodor dogs with Essential 6[®] spot-on once weekly 3. Malodor with placebo once weekly <ul style="list-style-type: none"> • Duration of the study 28 days. • Evaluated criteria : malodor score, microbial culture 	<p>Essential 6[®] spot-on acts on the cutaneous microbiota and diminishes bad odors.</p>
<p>Topical effect of a specific spot-on treatment made of natural ingredients in rabbits (Oryctolagus cuniculus) with skin problems: a pilot study</p> <p>G. SHEINBERG WAISBURD <i>et al.</i> <i>Veterinary world, 2020.</i></p>	<p>Evaluate the effect of Essential 6[®] spot-on in rabbits with kerato-seborrheic disorders.</p>	<ul style="list-style-type: none"> • 30 rabbits with dermatological skin disorders. • 15 rabbits with Essential 6[®] spot-on 1/week and • 15 other rabbits with no product • Duration of the study : 35 days • Evaluated criteria : cosmetic improvements 	<p>Essential 6[®] spot-on is effective on rabbits with skin disorders. It improves coat shine, hair loss, odor and squamosis.</p>

+ clinical cases

